Rate and Class Effect of ILD with Antibody Drug Conjugates
ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
